ChinaDrugStatus

Eplontersen sodium

依普隆特生钠
Brand: Wainua / 万诺维·Neurology / Rare Disease·Last verified 2026-11-20

Ligand-conjugated antisense therapy newly added to the 2026 Commercial Health Insurance Innovative Drug List (#24) for adult hereditary ATTR polyneuropathy.

China Approval (NMPA)

Approved
Approval Number(s)
国药准字HJ20250151
Initial Approval Date
Dec 22, 2025
Notice Published
Dec 22, 2025
MAH
AstraZeneca AB (阿斯利康)
Approved Scope
Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN) in adult patients.

National Reimbursement

Not Listed

Not included in the 2025 or 2026 National Reimbursement Drug List (basic medical insurance).

Commercial Insurance List

Announced · Effective Jan 1, 2027
2026 List Entry
#24 · 万诺维
Validity Period
2027-01-01 to 2028-12-31
MAH / Authorized Entity
AstraZeneca AB · 阿斯利康(无锡)贸易有限公司
Listed Indication Scope
Adult patients with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).

Catalog inclusion only. Actual reimbursement depends on individual commercial health insurance policy contracts.

Approved Products, Dosage Forms & Approval Numbers

1 verified NMPA record
Approval No.Dosage Form & StrengthEvent & ScopeApproval / Notice DateMAH & Source
国药准字HJ20250151
Injection (注射液)
Initial Approval

Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN) in adult patients.

适用于治疗成人遗传性转甲状腺素蛋白淀粉样变性多发性神经病(ATTRv-PN)患者。

Approved: 2025-12-22
Published: 2025-12-22
AstraZeneca AB

Change Timeline

  1. (2027-01-01)Commercial List· Catalog published: Nov 14, 2026

    2026 Commercial List · Newly Added (#24)

    Adult patients with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).

    Chinese original: 本品适用于治疗成人遗传性转甲状腺素蛋白淀粉样变性多发性神经病(ATTRv-PN)患者。

    NHSA · PDF p.4Verified 2026-11-20
  2. (2025-12-22)NMPA Approval

    NMPA Initial Marketing Approval (国药准字HJ20250151)

    Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN) in adult patients.

    Chinese original: 适用于治疗成人遗传性转甲状腺素蛋白淀粉样变性多发性神经病(ATTRv-PN)患者。

Verified Names & Aliases

Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.

依普隆特生钠注射液dosage name(NHSA)
Wainuabrand en(WHO)
万诺维brand zh(NHSA)

Primary Sources for This Record